Updated from ASH and ACCP – DOAC Dosing for VTE: What You Need to Know
Dr. Chokri Ben Lamine shared on X:
Based on ASH 2024 and ACCP 2021 Guidelines
”VTE Treatment (Therapeutic Anticoagulation)”
-Apixaban:
▸ 10 mg BID × 7 days → 5 mg BID
▸ Optional: 2.5 mg BID after 6 months (extended use)Rivaroxaban:
▸ 15 mg BID × 21 days → 20 mg OD
▸ Optional: 10 mg OD after 6 monthsEdoxaban:
▸ Parenteral anticoagulation × 5–10 days → 60 mg OD
▸ Reduce to 30 mg if CrCl 15–50 or weight ≤60 kgDabigatran:
▸ Parenteral anticoagulation × 5–10 days → 150 mg BIDVTE Prophylaxis (Post-op, High Risk)
-Apixaban: 2.5 mg BID-Rivaroxaban: 10 mg OD
-Dabigatran: 110 mg Day 1 → 220 mg OD
-Edoxaban: Not typically used for primary prophylaxis
Key Precautions
-Age >75-CrCl <30 mL/min
-Low body weight
-Active cancer → Consider LMWH
Always assess bleeding & renal function risk.”
You can Find more Posts on Hemostasis Today.
-
Apr 11, 2026, 13:51David McIntosh: Vital Plasma Derived Medicines – The Anomalous UK Scene
-
Apr 11, 2026, 13:47Samrawit Terefe: O Negative Blood Is the Universal Donor With Extreme Scarcity
-
Apr 11, 2026, 13:39Dheeraj Garg: Rethinking Cardiovascular Disease – A Cardiologist’s Perspective
-
Apr 11, 2026, 13:37Kushal Bhatia: Is The 4.5-Hour Thrombolysis Window Officially Outdated?
-
Apr 11, 2026, 13:35William Aird: Why Did Mammalian Red Blood Cells Give Up Their Nucleus?
-
Apr 11, 2026, 13:30Ken Kuang: Gravity Is Constant, But Your Vein Health Doesn’t Have to Be
-
Apr 11, 2026, 13:21Mascha Kern: Measuring Gender’s Role in Stroke and Migraine
-
Apr 11, 2026, 13:10Danique Steeghs: Key Findings from a Microfluidic Chemiluminescent Thrombin Generation Assay
-
Apr 11, 2026, 13:06Shanvi Mahi: A Validated Tool to Explore Lived Experiences After Stroke Rehabilitation